相关实验视频
瘤坏死因子-α和心力衰竭死亡率:一个社区研究
Shannon M Dunlay1, Susan A Weston, Margaret M Redfield
1Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minn., USA.
Circulation
|July 23, 2008
概括
在心力衰竭患者中,瘤坏死因子-α (TNFalpha) 的升高与死亡率的增加有关,并有助于对保存和减少射出分数 (EF) 的风险评估.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 生物标志物 生物标志物
背景情况:
- 瘤亡因子-α (TNFalpha),一种炎症性细胞因子,已知在心力衰竭 (HF) 中具有降低射出分数 (EF) 的升高,并与死亡率相关.
- 在社区环境中,关于TNFalpha水平及其对HF与保存EF (HFpEF) 的影响的数据有限.
研究的目的:
- 为了调查TNFalpha在社区基础的HF患者中升高的患病率.
- 检查TNFalpha水平与基线特征之间的关联.
- 确定TNFalpha在预测死亡率方面的预后价值及其在HF患者风险评估中的有用性.
主要方法:
- 预计将招募486名奥姆斯特德县居民,他们有活跃的HF (2004年7月至2007年3月).
- 测量临床特征和血清TNFαα水平.
- 统计分析以评估与基线特征,死亡率和风险预测模型的关联.
主要成果:
- 在29%的患者中发现TNFalpha (>2.8 pg/mL) 的升高.
- 较高的TNFα与肌素清除率降低,非吸烟,贫血和并发症增加相关.
- 较高TNFalpha四分位数的死亡风险显著增加,即使对年龄,性别和EF进行调整 (Ptrend=0.007).
- 在所有模型中,TNFalpha 改善了风险评估准确性 (P<0.05).
结论:
- 在社区HF患者中,TNFalpha在很大比例上升.
- 提升的TNFalpha与显著减少的生存率有关.
- 无论EF如何,TNFalpha为HF患者的风险评估提供了增量价值.
相关概念视频
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...